Pharmaceuticals Generic Industry Stocks($TEVA, $RDY, $TARO...): A Closer Look at the 10.89% Average Gain
The pharmaceuticals generic industry is a significant player in the global drug market. Generic drugs, which contain the same chemical substance as their patented counterparts, are sold at more affordable prices once the patents for the original drugs expire. This affordability has led to the vast popularity of generic drugs. As per the Center for Justice and Democracy at New York Law School, a staggering 80% of all prescribed drugs are generic, and they are the preferred choice 94% of the time when available. Companies in this sector, such as Zoetis, Inc., Allergan plc, and Mylan N.V., must demonstrate to the FDA that their products are effective substitutes for the original drugs.
Tickers in Industry - $TEVA, $RDY, $TARO, $ZTS, $ABEO
Swing Trader for Beginners: Trading in Markets Trending Down (TA&FA)
Notable Companies
Two of the standout companies in this industry are:
- ZOETIS (NYSE:ZTS)
- Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Market Capitalization
The pharmaceuticals generic industry has a diverse range of companies in terms of market capitalization. On average, the market cap across the theme is $12.3B. ZOETIS (ZTS) leads the pack with a valuation of $86.1B, while the smallest player, ACUR, is valued at just 39.6K.
Price Movements: Highs and Lows
The industry has seen varied price movements over different periods:
- Weekly average growth: 3.5%
- Monthly average growth: 5.97%
- Quarterly average growth: 18.19%
Some notable price movements include:
- Abeona Therapeutics (ABEO, $3.56) surged by 18.67% in a week, making it a top gainer among penny stocks.
- ZOETIS (ZTS, $182) faced a decline of 5.21% in a week.
- ZOETIS (ZTS, $183.51) also had a positive week, with its price jumping by 6.81%.
Volume Analysis
Trading volumes provide insights into the liquidity and investor interest in stocks. For the pharmaceuticals generic theme:
- Weekly average volume decline: -31.87%
- Monthly average volume growth: 4.08%
- Quarterly average volume growth: 22.36%
A notable volume trend was observed for Dr. Reddy's Laboratories, which saw its stock volume increase consecutively for five days, with daily gains ranging from 92% to 94%.
Fundamental Analysis Ratings
Investors often rely on fundamental analysis ratings to gauge the health and potential of companies. For the pharmaceuticals generic industry, the ratings range from 1 (best) to 100 (worst). The specific average ratings for companies within this theme are not provided in the text.
In conclusion, the pharmaceuticals generic industry has shown resilience and growth, with an average gain of 10.89% in the past month. With major players like ZOETIS and Teva leading the way, the industry continues to be a significant contributor to the global pharmaceutical market.
TEVA - On August 28, 2023, TEVA's Momentum Indicator crossed the pivotal 0 mark, hinting at a possible upward trajectory for the stock. Investors might contemplate acquiring the stock or considering call options. Historical data from Tickeron's A.I.dvisor, analyzing 78 analogous events, reveals that the stock ascended in 58 instances post such a shift. This places the likelihood of an upward move at an impressive 74%.
RDY - On August 24, 2023, RDY's 10-day RSI Oscillator transitioned from the overbought region, suggesting a potential shift from an upward to a downward trend. Investors might consider offloading the stock or exploring put options. Historical analysis by Tickeron's A.I.dvisor, examining 36 similar transitions, showed that in 21 instances, the stock declined in subsequent days. This data indicates a 58% probability of a downward movement.
TARO - On August 25, 2023, TARO's 10-day Moving Average made a bullish crossover above its 50-day counterpart. This suggests a potential upward momentum and may serve as a buying cue for investors. Historical data reveals that in 8 out of 14 previous occurrences of such a crossover, TARO's stock sustained its rise over the subsequent month. This presents a 57% likelihood of the stock maintaining its upward trajectory.
